Drug Eluting Stent Event Registry of Thrombosis
Principal Investigator: Janet Strain, MD Eligibility: Includes development of a clot inside a drug eluting stent. Description: Data collection on patients who have experienced stent thrombosis.
For more information, please call 201-447-8453.
Improved Reduction of Outcomes: Vytorin Efficacy International Trial. A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (ezetimibe/simvastatin) vs. Simvastatin Monotherapy in High-Risk Patients Presenting with Acute Coronary Syndrome. Merck. Shering-Plough Research Institute. PI. Michael Kesselbrenner, MD.
The purpose of this study is to compare two drugs, ezetimibe/simvastatin combination 10/40mg (sold as Vytorin) and simvastatin 40mg (sold as Zocor).
Eligibility: Recent admission to the hospital for acute coronary syndrome Description: Patients are randomized to one of the two approved drugs and followed for several years.
Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (Translate-ACS) Registry
Principal Investigator: Michael Kesselbrenner, MD Eligibility: Admitted with acute coronary syndrome or heart attack, taken for a stent, and are receiving an antiplatelet medication. Description: Patients are enrolled prior to discharge, then are followed by Duke University with 4 telephone calls over 15 months.
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome (ACS) Subjects with Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) Who are Medically Managed. Eli Lilly and Co. PI. Michael Kesselbrenner, MD
The purpose of this study is to determine whether prasugrel can help patients with a heart attack or symptoms associated with a threatened heart attack by reducing death, future heart attack, or stroke, whether prasugrel is safe or has any side effects that might be associated with it, how prasugrel affects certain blood cells in your body, called platelets, and how prasugrel affects your daily quality of life.
Eligibility: Recent admission to the hospital for acute coronary syndrome. Patients are receiving medical treatment. Description: Patients are randomized to one of the two approved drugs and followed for several years.
The Vest Prevention of Early Sudden Death Trial
Principal Investigator: Gerald Sotsky, MD Eligibility: Admitted with acute coronary syndrome or heart attack with a weak heart muscle. Description: To find out whether wearing a defibrillator vest can prevent death from an abnormal heart rhythm in the three months following a heart attack.
Variation in Recovery: Role of Gender on Outcomes of Young Acute Myocardial Infarction (AMI) Patients. Yale University/Yale-New Haven Hospital. PI. Gerald Sotsky, MD
The purpose of this study is to help researchers and doctors better understand the period of time after your heart attack (recovery period).
Eligibility: Patients less than 55 years old admitted to the hospital for a heart attack Description: Patient agrees to questionnaires and blood work.
Evaluation of the Safety and Efficacy of Short-Term A-002 Treatment in Subjects with Acute Coronary Syndromes
Principal Investigator: Janet Strain, MD Eligibility: Admitted with acute coronary syndrome or heart attack. Description: Patients are randomized to a new oral anti-inflammatory drug or placebo. Patients remain on study drug for 16 weeks.